Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
17
MAZE Quote, Financials, Valuation and Earnings
Last price:
$10.93
Seasonality move
:
--
Day range:
$9.73 - $12.05
52-week range:
$6.71 - $17.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
147.2K
Avg. volume:
159.1K
1-year change:
--
Market cap:
$427M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MAZE
Maze Therapeutics
|
-- | -$0.63 | 25% | -1571.33% | $25.00 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
IFRX
InflaRx NV
|
$36.3K | -$0.20 | 256.48% | -10.49% | $3.62 |
|
LENZ
LENZ Therapeutics
|
-- | -$0.32 | -- | -26.67% | $44.63 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$0.48 | -- | -42.18% | $39.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MAZE
Maze Therapeutics
|
$9.97 | $25.00 | $427M | -- | $0.00 | 0% | -- |
|
CDT
Conduit Pharmaceuticals
|
$3.25 | -- | $2.6M | -- | $0.00 | 0% | -- |
|
IFRX
InflaRx NV
|
$0.80 | $3.62 | $54.4M | -- | $0.00 | 0% | 265.10x |
|
LENZ
LENZ Therapeutics
|
$29.20 | $44.63 | $821.9M | -- | $1.03 | 0% | -- |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$10.96 | $39.50 | $410.3M | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MAZE
Maze Therapeutics
|
-- | 0.000 | -- | -- |
|
CDT
Conduit Pharmaceuticals
|
-- | 0.069 | -- | -- |
|
IFRX
InflaRx NV
|
-- | 1.638 | -- | 3.85x |
|
LENZ
LENZ Therapeutics
|
-- | 0.835 | -- | -- |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -0.312 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MAZE
Maze Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
CDT
Conduit Pharmaceuticals
|
-- | -$4M | -- | -- | -- | -$4.3M |
|
IFRX
InflaRx NV
|
-$9.8K | -$13.7M | -56.78% | -56.78% | 1207051.66% | -$14.8M |
|
LENZ
LENZ Therapeutics
|
-- | -$16.9M | -- | -- | -- | -$16.2M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$25.1M | -- | -- | -- | -$20.9M |
Maze Therapeutics vs. Competitors
-
Which has Higher Returns MAZE or CDT?
Conduit Pharmaceuticals has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics-- -- -- CDTConduit Pharmaceuticals-- -$19.80 -- -
What do Analysts Say About MAZE or CDT?
Maze Therapeutics has a consensus price target of $25.00, signalling upside risk potential of 150.75%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Maze Therapeutics is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics3 0 0 CDTConduit Pharmaceuticals0 0 0 -
Is MAZE or CDT More Risky?
Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MAZE or CDT?
Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or CDT?
Maze Therapeutics quarterly revenues are --, which are smaller than Conduit Pharmaceuticals quarterly revenues of --. Maze Therapeutics's net income of -- is lower than Conduit Pharmaceuticals's net income of -$5.1M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics-- -- -- -- CDTConduit Pharmaceuticals-- -- -- -$5.1M
-
Which has Higher Returns MAZE or IFRX?
InflaRx NV has a net margin of -- compared to Maze Therapeutics's net margin of -14092.9%. Maze Therapeutics's return on equity of -- beat InflaRx NV's return on equity of -56.78%.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics-- -- -- IFRXInflaRx NV-5376.61% -$0.14 $63.9M -
What do Analysts Say About MAZE or IFRX?
Maze Therapeutics has a consensus price target of $25.00, signalling upside risk potential of 150.75%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 350.85%. Given that InflaRx NV has higher upside potential than Maze Therapeutics, analysts believe InflaRx NV is more attractive than Maze Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics3 0 0 IFRXInflaRx NV5 1 0 -
Is MAZE or IFRX More Risky?
Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.694%.
-
Which is a Better Dividend Stock MAZE or IFRX?
Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or IFRX?
Maze Therapeutics quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of -$450. Maze Therapeutics's net income of -- is lower than InflaRx NV's net income of -$8.7M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus 265.10x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics-- -- -- -- IFRXInflaRx NV265.10x -- -$450 -$8.7M
-
Which has Higher Returns MAZE or LENZ?
LENZ Therapeutics has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics-- -- -- LENZLENZ Therapeutics-- -$0.53 -- -
What do Analysts Say About MAZE or LENZ?
Maze Therapeutics has a consensus price target of $25.00, signalling upside risk potential of 150.75%. On the other hand LENZ Therapeutics has an analysts' consensus of $44.63 which suggests that it could grow by 52.83%. Given that Maze Therapeutics has higher upside potential than LENZ Therapeutics, analysts believe Maze Therapeutics is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics3 0 0 LENZLENZ Therapeutics5 0 0 -
Is MAZE or LENZ More Risky?
Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MAZE or LENZ?
Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Maze Therapeutics pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or LENZ?
Maze Therapeutics quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Maze Therapeutics's net income of -- is lower than LENZ Therapeutics's net income of -$14.6M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics-- -- -- -- LENZLENZ Therapeutics-- -- -- -$14.6M
-
Which has Higher Returns MAZE or LIMN?
Liminatus Pharma has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics-- -- -- LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About MAZE or LIMN?
Maze Therapeutics has a consensus price target of $25.00, signalling upside risk potential of 150.75%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics has higher upside potential than Liminatus Pharma, analysts believe Maze Therapeutics is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics3 0 0 LIMNLiminatus Pharma0 0 0 -
Is MAZE or LIMN More Risky?
Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MAZE or LIMN?
Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or LIMN?
Maze Therapeutics quarterly revenues are --, which are smaller than Liminatus Pharma quarterly revenues of --. Maze Therapeutics's net income of -- is lower than Liminatus Pharma's net income of --. Notably, Maze Therapeutics's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics-- -- -- -- LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns MAZE or ORKA?
Oruka Therapeutics has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAZEMaze Therapeutics-- -- -- ORKAOruka Therapeutics-- -$0.40 -- -
What do Analysts Say About MAZE or ORKA?
Maze Therapeutics has a consensus price target of $25.00, signalling upside risk potential of 150.75%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 260.4%. Given that Oruka Therapeutics has higher upside potential than Maze Therapeutics, analysts believe Oruka Therapeutics is more attractive than Maze Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings MAZEMaze Therapeutics3 0 0 ORKAOruka Therapeutics7 0 0 -
Is MAZE or ORKA More Risky?
Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of -0.380, suggesting its less volatile than the S&P 500 by 137.95%.
-
Which is a Better Dividend Stock MAZE or ORKA?
Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Maze Therapeutics pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAZE or ORKA?
Maze Therapeutics quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. Maze Therapeutics's net income of -- is lower than Oruka Therapeutics's net income of -$21M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAZEMaze Therapeutics-- -- -- -- ORKAOruka Therapeutics-- -- -- -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is up 1.68% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 14.47% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is down 1.29% over the past day.
